1) Performance Overview
- GE HealthCare reported Q1 2026 revenue of $5.1 billion, reflecting 2.9% organic growth year-over-year, driven by strong demand in pharmaceutical diagnostics, advanced visualization solutions, and imaging businesses.
- Orders grew 1.1%, with a book-to-bill ratio of 1.07x and a record backlog of $21.8 billion, up $1.2 billion YoY.
- Adjusted EBIT margin was 13.5%, down 150 basis points YoY, and adjusted EPS was $0.99, impacted by a supplier recall and inflationary pressures.

2) Strategic Initiatives and Innovations
- GE HealthCare is advancing its growth strategy with significant milestones in its Precision Care pipeline, including regulatory clearances for the Photonova Spectra CT platform and next-generation MRI technologies.
- The company is focused on enhancing customer experience and has seen a nearly 80% increase in doses of Flyrcado since January, with a target of $500 million in annual revenue by 2028.
- The acquisition of Intelerad aims to create a connected cloud-first enterprise imaging ecosystem, enhancing AI, cloud, and software capabilities.

3) Challenges and Headwinds
- Profit performance was negatively impacted by a $100 million recall related to a PDx supplier and rising material costs, including a $100 million increase in memory chip prices and $50 million from other inflationary pressures.
- The company is taking a cautious approach to its guidance, reducing adjusted EPS expectations by $0.15 due to ongoing inflation impacts, while still anticipating mid- to high single-digit adjusted EPS growth for the year.

4) Financial Guidance and Outlook
- GE HealthCare maintains its organic sales growth guidance of 3% to 4% for 2026 but has reduced its adjusted EBIT margin outlook to 15.4% to 15.7%.
- The adjusted EPS guidance has been revised to a range of $4.80 to $5.00, reflecting a 5% to 9% growth YoY.
- The company expects free cash flow of approximately $1.6 billion in 2026, with a focus on managing inflationary pressures through pricing and cost actions.

5) Conclusion and Missing Information
- The earnings call highlighted a strong start to 2026 with solid revenue growth and strategic advancements, but challenges from inflation and supply chain issues have led to a more cautious outlook.
- Bottom line: GE HealthCare is positioned for growth with innovative products and a strong backlog, but must navigate inflationary pressures and operational challenges to meet its revised financial targets.